In prostate cancer, an intracellular form of CD44—released upon extracellular domain cleavage—is transported into the nucleus, where it can bind to RUNX2 leading to its activation and subsequent increased MMPs expression [29]. Here, RUNX2 is linked to Familial prostate cancer.